Overview & Introduction
Congenital Cytomegalovirus (cCMV)
Congenital CMV is the most common viral infection infants are born with in the United States. While many babies show no symptoms at birth, cCMV can lead to significant long-term health challenges, including hearing loss and developmental delays. Understanding the prevalence and impact is the first step in effective clinical management.
Clinical Features & Diagnosis
Recognizing the clinical presentation and implementing timely diagnostic testing is essential for managing congenital CMV. Early identification allows for intervention that can significantly improve long-term neurodevelopmental outcomes.
Common Clinical Signs
Approximately 10% of infants are symptomatic at birth. Clinical manifestations include microcephaly, sensorineural hearing loss, petechiae, jaundice, and hepatosplenomegaly. Infants may also present with intrauterine growth restriction (IUGR) or chorioretinitis.
Diagnostic Testing
Gold standard diagnosis requires detection of CMV DNA by PCR in saliva or urine within the first 2-3 weeks of life. Positive results after this window may represent postnatal acquisition. Saliva PCR is highly sensitive but requires a confirmatory urine test due to potential contamination from breast milk.
Clinical Imaging
Head ultrasound or MRI may reveal intracranial calcifications or ventriculomegaly.
Hearing Checks
Auditory brainstem response (ABR) testing is required to assess for sensorineural hearing loss.
Treatment & Clinical Management
Antiviral Therapy and Supportive Care
Current management strategies focus on minimizing long-term sequelae through early intervention. Antiviral treatment with valganciclovir for 6 months is often indicated for infants with symptomatic central nervous system involvement. Management also includes longitudinal monitoring of hearing and neurodevelopmental progress to ensure comprehensive support through the first years of life.
Prevention & Long-Term Outcomes
- Practice frequent hand hygiene, especially after contact with saliva or diapers.
- Avoid sharing food, utensils, or pacifiers with young children to reduce transmission risk.
- Schedule regular audiology screenings to monitor for delayed-onset hearing loss.
- Coordinate with neurodevelopmental specialists for early intervention and support.
- Maintain consistent ophthalmology follow-ups to detect potential vision changes.
Congenital CMV Frequently Asked Questions
What is the most effective window for antiviral treatment in newborns?
Clinical guidelines suggest that starting antiviral therapy within the first month of life (ideally before 28 days) provides the best outcomes for protecting hearing and neurodevelopmental health.
How often should asymptomatic newborns be screened for hearing loss?
Even if the initial newborn hearing screen is passed, infants with confirmed cCMV should undergo regular audiologic monitoring every 3-6 months for the first few years, as hearing loss can be late-onset or progressive.
What prevention strategies are most effective during pregnancy?
The primary focus is on behavioral hygiene: avoiding contact with saliva and urine of young children, frequent handwashing, and not sharing food or utensils, as toddlers are a common source of CMV infection.